InMed Pharmaceuticals share price logo

InMed Pharmaceuticals

NASDAQ: INM

$1.32

-0.01

(-0.75%)

as on

InMed Pharmaceuticals Stock Performance

as on October 19, 2026 at 2:15 pm IST

  • Day's High

    $1.32
    $1.34

    1.52%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.58
    $2.33
    downward going graph

    56.44%

    Downside

    76.52%

    Upside

    downward going graph

InMed Pharmaceuticals share price movements today

Previous Close
$1.33
Open
$1.34
Volume
68.8K
Market Cap
$7.3M
Day's Low - High
$1.32 - $1.34
52 Week Low - High
$0.58 - $2.33

InMed Pharmaceuticals Historical Returns

1 Month Return
-5.04 %
3 Month Return
-13.16 %
1 Year Return
-37.14 %
3 Year Return
-89.75 %
5 Year Return
-99.81 %

InMed Pharmaceuticals Stock Fundamentals & Key Indicators

Check InMed Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.3M

EPS (TTM)

-3.4828

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.38

Industry PE ratio

-7.57

PEG Ratio

-0.00

EBITDA

-9.8M

Revenue (TTM)

2.1B

Profit Margin

14.92%

Return On Equity TTM

-134.73%

InMed Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of InMed Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Sell$7.3M-99.81%-0.3814.92%0.00%
Buy$39.3BNA61.0147.54%1.13%
Buy$23.2B184.98%17.9186.14%0.00%
Buy$20.0B38.60%-50.6134.83%2.63%
Buy$42.3BNA20.6665.57%1.99%

Stock Returns calculator for InMed Pharmaceuticals Stock including INR - Dollar returns

The InMed Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

InMed Pharmaceuticals investment value today

Current value as on today

₹67,925

Returns

-₹32,075

(-32.07%)

Returns from InMed Pharmaceuticals Stock

-₹37,143 (-37.14%)

Dollar Impact

₹5,068 (+5.07%)

Analyst Recommendation on InMed Pharmaceuticals Stock

Based on 8 analysts

SELL

0.00%

Buy

37.50%

Hold

62.50%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'SELL' rating for InMed Pharmaceuticals. Average target price of $20

InMed Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on InMed Pharmaceuticals.

What analysts predicted

93.4%UPSIDE

Target Price

$20

Current Price

$1.32

Analyzed by

8 Analysts

Target

$20.00

InMed Pharmaceuticals target price $20, a slight upside of 93.4% compared to current price of $1.32. According to 8 analysts rating.

Indian Investors' Interest in InMed Pharmaceuticals Stock

Search interest for InMed Pharmaceuticals Stock has increased by 8% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:8% versus previous 30 day period

InMed Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
1
1
1
1
1
1
1
1
-
2,057
Gross Profit
0
0
0
0
0
0
0
0
-
306
Operating Income
-1
-2
-1
-2
-2
-2
-1
-2
-2
-3
EBITDA
-1
-1
-1
-2
-1
-2
-1
-2
-2
-2
Interest Expense
-
-
-
0
-
0
-
-
-
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-1
-1
-1
-2
-2
-2
-1
-2
-2
-4
Income Tax Expense
-
0
-
-
-
-
-
-
-
-
Net Income
-1
-1
-1
-2
-2
-2
-1
-2
-2
-5
Net Profit Margin
24.69%
36.32%
39.02%
41.46%
13.92%
44.20%
35.99%
3.19%
0.00%
14.92%

InMed Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Jun 2026
Total Revenue
-
-
-
-
-
1
4
4
4
3,176
Gross Profit
0
0
0
0
-
0
1
1
1
709
Operating Income
-4
-8
-13
-9
-12
-13
-8
-8
-7
-9
EBITDA
-3
-8
-10
-8
-12
-18
-7
-7
-7
-9
Interest Expense
-
-
-
0
0
-
-
-
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-4
-8
-13
-8
-12
-18
-7
-7
-8
-11
Income Tax Expense
-
-
-
-
-
-
0
0
-
-
Net Income
-3
-8
-10
-8
-12
-18
-7
-7
-8
-12
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
49.89%
33.93%
23.94%
34.53%
22.35%

InMed Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-1
-1
-1
-2
-2
-1
-2
-3,753
-2
-14,581
Operating Cash Flow
-1
-1
-1
-2
-1
-1
-2
-3
-1
-2
Investing Cash Flow
-
0
-
-
-
-
-
-
-
-
Financing Cash Flow
0
0
0
0
2
8
0
0
0
0
Change in Cash
-1
-1
0
-2
1
6
-2
-3
-1
-2

InMed Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Jun 2026
Net Income
-3
-6
-10
-8
-10
-18
-7
-7
-8
-12,560
Operating Cash Flow
-2
-3
-6
-7
-9
-15
-7
-6
-7
-8,643
Investing Cash Flow
0
-1
-2
3
0
0
0
0
-
-
Financing Cash Flow
7
19
0
0
10
15
10
4
12
94
Change in Cash
5
13
-11
-4
1
-1
2
-2
4
-8,549

Global Institutional Holdings in InMed Pharmaceuticals

Check out the Institutions with significant holdings in InMed Pharmaceuticals.

Funds
Holdings
Banque Cantonale Vaudoise
0.00%
Virtu Financial LLC
0.37%
Squadron Capital Management LLC
5.92%
TWO SIGMA SECURITIES, LLC
0.35%
Tower Research Capital LLC
0.00%

InMed Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 22 July

    Thu, 00:16 AM

    -

    Mentari Therapeutics raises $200 million before merging with InMed Pharmaceuticals, enhancing its migraine treatment pipeline.

Insights on InMed Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.12M → 2.05B (in $), with an average increase of 56.1% per quarter

  • imgPOSITIVE IMPACT

    Promoter Holding Up

    img

    Promoters have increased holdings from 68.54% to 69.47% in Mar 2026 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, INM stock has moved up by 85.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, SANDOZ GROUP AG SPONSORED ADS Switzerland has given 100.4% return, outperforming this stock by 189.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 83.4% return, outperforming this stock by 120.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, INM stock has moved down by -60.1%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 26.20% to 26.13% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 5.26% to 4.40% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, -1.72M → -5.08M (in $), with an average decrease of 46.4% per quarter

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
OrganisationInMed Pharmaceuticals
Headquarters815 West Hastings Street, Vancouver, BC, V6B 0M3, CA
IndustryDrug Manufacturers - Specialty & Generic
CEOEric A. Adams Chem.

Key Management of InMed Pharmaceuticals

Name

Title

Ms. N. Netta Jagpal

CFO & Corporate Secretary

Mr. Michael Woudenberg P.Eng.

Chief Operating Officer

Dr. Eric Chih-Hsien Hsu Ph.D.

Senior Vice President of Preclinical Research & Development

Dr. Sazzad Hossain M.Sc., Ph.D.

Co-Founder

Mr. Colin Clancy

VP of Investor Relations & Corporate Communications

Mr. Jerry P. Griffin

Vice President of Sales & Marketing

Mr. Eric A. Adams B.S. Chem., M.I.B.

President, CEO & Director

FAQs

What is InMed Pharmaceuticals share price today?

InMed Pharmaceuticals share price today is $1.32 as on at the close of the market. InMed Pharmaceuticals share today touched a day high of $1.34 and a low of $1.32.

What is the 52 week high and 52 week low for InMed Pharmaceuticals share?

InMed Pharmaceuticals share touched a 52 week high of $2.33 on and a 52 week low of $0.58 on . InMed Pharmaceuticals stock price today i.e. is closed at $1.32,which is 43.35% down from its 52 week high and 129.57% up from its 52 week low.

What is InMed Pharmaceuticals's market capitalisation today?

InMed Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in InMed Pharmaceuticals Stock (INM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for InMed Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy InMed Pharmaceuticals Stock (INM) from India?

Indian investors can start investing in InMed Pharmaceuticals (INM) shares with as little as ₹94.959999084473 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in InMed Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on InMed Pharmaceuticals share’s latest price of $1.32 as on October 19, 2026 at 8:45 am IST, you will get 7.5758 shares of InMed Pharmaceuticals. Learn more about fractional shares .

What are the returns that InMed Pharmaceuticals has given to Indian investors in the last 5 years?

InMed Pharmaceuticals stock has given -99.81% share price returns and 26.39% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?